Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

被引:7
作者
Li, Min [1 ]
Zhou, Na [2 ]
Duan, Shengnan [1 ]
Zhong, Hua [3 ]
Jiang, Rong [4 ,5 ]
Yuan, Ni [1 ]
机构
[1] Dalian Med Univ, Sch Publ Hlth, Dalian, Liaoning, Peoples R China
[2] Peking Univ, Dept Hlth Policy & Management, Beijing, Peoples R China
[3] Dalian Med Univ, Off Case Files Management, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China
[4] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Jiangsu, Peoples R China
[5] China Pharmaceut Univ, Res Ctr Natl Drug Policy & Ecosyst, Nanjing, Peoples R China
来源
BMJ OPEN | 2022年 / 12卷 / 12期
关键词
SOCIAL MEDICINE; HEALTH ECONOMICS; PUBLIC HEALTH; DIAGNOSIS; TIME;
D O I
10.1136/bmjopen-2022-066335
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019.Study designObservational study based on the Global Burden of Disease.SettingThe relevant incidence, prevalence, death and disability-adjusted life year (DALY) rates and corresponding age-standardised rates (ASRs) and sociodemographic index (SDI) in China, globally and in Asia-Pacific countries were extracted from the GBD2019 Database to further study the age-standardised incidence, prevalence and mortality, and the relationship between DALY rate and SDI.ResultsVarious disease burden indicators of multiple sclerosis in China are at low level in the world, and the prevalence, incidence and DALY rates have slowly increased from 1990 to 2019. During this period, the age-standardised prevalence rate (ASPR) of multiple sclerosis in China showed an upward trend, while the age-standardised death rate (ASDR), age-standardised DALY rate (ASR-DALY) and age-standardised incidence rate all decreased to varying degrees, which were roughly consistent with the global amplitude changes, and all indicators are similar to most countries in the Asia-Pacific region. As the value of the SDI increases, the ASPR of multiple sclerosis was trending upward, and the ASDR was trending downward.ConclusionCompared with other countries in the Asia-Pacific region, China is in a low state of disease burden indicators. However, as a developing country and the most populous country in the world, the total number of patients is not small, and as a rare disease, the treatment cost is relatively expensive, and the treatment cost of the complications caused by the disease is not low. The construction of the medical security system should be strengthened to reduce its burden on individuals, families and society.
引用
收藏
页数:8
相关论文
共 17 条
  • [1] Diagnosis of multiple sclerosis: progress and challenges
    Brownlee, Wallace J.
    Hardy, Todd A.
    Fazekas, Franz
    Miller, David H.
    [J]. LANCET, 2017, 389 (10076) : 1336 - 1346
  • [2] Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review
    Eskandarieh, Sharareh
    Heydarpour, Pouria
    Minagar, Alireza
    Pourmand, Shadi
    Sahraian, Mohammad Ali
    [J]. NEUROEPIDEMIOLOGY, 2016, 46 (03) : 209 - 221
  • [3] ghdx.healthdata, Global Burden of Disease Study 2019 (GBD 2019) Data Resources | GHDx
  • [4] Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017-continuity and change
    Hartung, Hans-Peter
    Graf, Jonas
    Aktas, Orhan
    Mares, Jan
    Barnett, Michael H.
    [J]. CURRENT OPINION IN NEUROLOGY, 2019, 32 (03) : 327 - 337
  • [5] China has officially released its first national list of rare diseases
    He, Jiangjiang
    Kang, Qi
    Hu, Jiahao
    Song, Peipei
    Jin, Chunlin
    [J]. INTRACTABLE & RARE DISEASES RESEARCH, 2018, 7 (02) : 145 - 147
  • [6] Negotiating prices of drugs for rare diseases
    Henrard, Severine
    Arickx, Francis
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2016, 94 (10) : 779 - 781
  • [7] Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson, Wills
    Palma, Ana
    Schuurman, Ad
    Simoens, Steven
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2012, 7
  • [8] Multiple Sclerosis: Current Knowledge and Future Outlook
    Kamm, Christian P.
    Uitdehaag, Bernard M.
    Polman, Chris H.
    [J]. EUROPEAN NEUROLOGY, 2014, 72 (3-4) : 132 - 141
  • [9] Kurtzke JF, 2000, J NEUROVIROL, V6, pS134
  • [10] Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy)
    Moccia, Marcello
    Affinito, Giuseppina
    Ronga, Bruno
    Giordana, Roberta
    Fumo, Maria Grazia
    Lanzillo, Roberta
    Petracca, Maria
    Carotenuto, Antonio
    Triassi, Maria
    Morra, Vincenzo Brescia
    Palladino, Raffaele
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (04) : 597 - 607